Type 2 Diabetes

Don't lose your way when guiding T2DM patients to the right diet for them.

The US Food and Drug administration today issued a warning that the type 2 diabetes medicines sitagliptin (Januvia/Merck) linagliptin (Tradjenta/BI), and alogliptin (Nesina/Takeda) "may cause joint pain that can be severe and disabling."

The US Food and Drug Administration approved a new glycemic control treatment for type 2 diabetes for adults, a combination product made of empagliflozin (Jardiance/ Boehringer Ingelheim) and metformin hydrochloride. It will be marketed as Synjardy in a joint venture with Eli Lilly.

With a rallying cry of "Hands off Our Legs" protestors are due to picket the US Department of Health and Human Services over a proposed Medicare rule change that would affect amputees.

Your patients can't hear this from you enough – exercise improves diabetes control.

Three new studies provide evidence to help convince your patients about the importance of healthy eating.

A new study looks to explain why patients might lose less weight than expected during SGLT2 therapy.

Finding more effective therapies for preventing diabetic nephropathy would be attractive, and a recent study has pointed to SGLT2 inhibitors as promising candidates in this area.

The following slideshow covers findings of 3 recent studies on various complications associated with type 2 diabetes.

Our blogger discusses the emotional component of caring for patients with a chronic disease.

“In brief, the risk for T2DM is a combination of both person and place, and our national strategies need to understand and intervene across these levels.”

A sleep apnea device may effectively slow the progression of diabetes in at risk patients.

"Assisting others is its own reward, beyond measure." Our blogger shares his views on the value of mentoring.

Study shows intramuscular injected bone marrow-derived mesenchymal stem cells may be able to restore the myelin sheath and nerve cells in diabetic sciatic nerves.

It may be cool to sip on a Coca-Cola that features your name right on the product, but a report that's been making the rounds details the metabolic roller coaster ride that drinking even a single can unleashes on the body.

This quiz will help you better assess whether or not to prescribe an SGLT2 inhibitor for your type 2 diabetes patients.

How will pay-for-performance affect specialists who treat the more challenging patients? Our blogger shares her thoughts and concerns.

A new investigation of the molecular and cellular mechanisms that produce diabetes may explain the strong association between cystic fibrosis and pancreatic complications.

With obesity on the rise, bringing with it an increased risk of diabetes, cardiovascular disease, and other conditions, food labels may soon get a facelift.

Advances in delivery methods renewed interest in the development of an inhaled form of insulin. We explore the history, pros and cons, and future of this fast-acting, short-duration drug.

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.

Catch up on some of the latest headlines in diabetes care, including updates in pediatric management and an artificial pancreas.

A study evaluating glycemic response following insulin initiation for type 2 diabetes mellitus found that patients with higher depression parameters or distress at baseline had significantly higher rates of microvascular complications at baseline and higher HbA1c levels.

Decreased vasoregulation in the brain leads to increased inflammation and loss of cognitive function in older adults with type 2 diabetes mellitus.

What is the best way to treat a diabetic patient who has a metformin intolerance? Test your knowledge of alternative monotherapies, including SGLT2 inhibitors, GLP-1 agonists, and sulfonylureas.

Treating patients with obesity or diabetes is no easy task for doctors despite the large number of options available to them and their patients. Taking into account the demographics of the patient population as well as the overall health of their individual patient.

Two recent cases advise against off-label use of SGLT2 inhibitors for T1DM patients and discuss possible mechanisms for the rare occurrence of euglycemic diabetic ketoacidosis.

Weigh in on how you would manage this patient’s situation.